AbbVie's Skyrizi continues to deliver robust revenue growth, with Q2 2026 net sales reaching $5.51 billion, up 24.5% year-over-year, supported by expanding market share in psoriasis, Crohn's disease, and other immunology indications. Analyst consensus estimates peg Q3 2026 global Skyrizi revenues near $5.71 billion, implying roughly 21% growth from the prior-year quarter amid sustained demand and limited near-term biosimilar pressure. Recent Phase 3 AFFIRM trial data demonstrated strong endoscopic remission rates with subcutaneous induction dosing, bolstering regulatory submissions and reinforcing the drug's competitive positioning against agents such as J&J's Tremfya. AbbVie's full Q3 results, due October 30, will provide the definitive figure, with traders monitoring any sequential acceleration or competitive headwinds that could shift the outcome relative to the market threshold.